Dyne Therapeutics Inc. is advancing novel therapeutics for people living with genetically driven neuromuscular diseases. Representatives from the company recently presented a poster showcasing preclinical and early clinical results from the development of their proprietary FORCE platform applied to Duchenne muscular dystrophy (DMD).
Navigo Proteins GmbH has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to advance the preclinical development of next-generation radiotheranostics using the Auger-electron emitting radioisotope Terbium (161Tb).
The synthesis of RP-1664, a highly potent, selective and bioavailable PLK4 inhibitor for the potential treatment of cancer, was recently reported by Repare Therapeutics Inc.
Prelude Therapeutics Inc. described the discovery of PRT-3789, a first-in-human, highly potent and selective SMARCA2-targeted protein degrader, for the potential treatment of cancer.
An Institut Pasteur team has developed an original vaccine platform known as MOPEVAC, that will strengthen the organization’s pandemic preparedness initiatives, with the platform’s first vaccine candidate, which targets Lassa fever, set to enter the clinic.
The aberrant expression of partner of NOB1 homolog (PNO1) is known to promote oncogenesis in the colorectum and the esophagus, but its involvement in ovarian cancer and the mechanisms behind it are not well known. Chinese researchers investigated the role of PNO1 in ovarian cancer development and progression in the preclinical setting.
The ability of influenza virus to rapidly undergo antigenic shift to evade immunity raises the need for effective influenza antivirals with a broad spectrum. In a recent Nature Microbiology article, Cidara Therapeutics Inc. provided preclinical data for their drug-Fc conjugate compound CD-388, which has the potential to be a robust therapeutic option for the universal prevention of both seasonal and pandemic influenza.
Filamon Pty. Ltd. has described lysosomal targeting peptides (LYTAPs) acting as EGFR (HER1; erbB1) degradation inducers reported to be useful for the treatment of cancer.
Baoyuan Biomedical Technology (Hangzhou) Co. Ltd. has identified serine/threonine-protein kinase ULK inhibitors reported to be useful for the treatment of cancer.
RSS
